Unihealth's Ugandan receivables hit 320 days; Tanzania plant scrapped
FY26 profit surged 83%, but the 1,000-bed expansion is now three years late and a key African bet has been abandoned.
What's new
- 1,000-bed expansion target pushed from FY25-26 to calendar 2028.
- Uganda receivables days blew out to 320 from a prior 120-135.
- Tanzania syringe manufacturing plan scrapped; replaced by a 20-bed clinic.
Why this matters
The core hospital business is delivering strong profit growth, but the international expansion story is unravelling. A receivable cycle of 320 days in Uganda is a serious cash-flow problem, and abandoning a promoted manufacturing facility without explanation raises governance questions. The revised bed expansion timeline delays the growth thesis by three years.
What we're watching
- Whether the Uganda receivables collection improves or becomes a write-down risk.
- Regulatory approval for the 20-bed Mwanza facility in Tanzania.
- Progress on the 100-bed Dar es Salaam acquisition, which is at final legal stages.
The full read
Unihealth Hospitals' FY26 numbers are strong. Revenue climbed 34.6% to ₹137 crore, margins expanded 400 bps to 42.9%, and profit surged 83%. But the conference call revealed several problems behind that headline. The 1,000-bed expansion, a key part of the growth story, is now delayed by three years to calendar 2028. In Uganda, receivable days have ballooned to 320 from a previously disclosed 120-135. That's nearly a year of unpaid bills. A serious cash-flow risk. In Tanzania, a previously promoted syringe manufacturing facility has been scrapped without explanation. Management is now pitching a 20-bed clinic in Mwanza and a 100-bed acquisition in Dar es Salaam. The domestic business is firing on all cylinders. The international footprint is generating operational headaches and governance questions. The next test is whether the Ugandan receivables collection problem becomes a write-down.
Questions answered
- How did the core Indian hospital business perform in FY26?
- Revenue grew 34.6% to ₹137 crore, EBITDA margin expanded 400 basis points to 42.9%, and profit after tax jumped 83%. The Indian operations are clearly performing well.
- What happened to the 1,000-bed expansion plan?
- The target, originally set for fiscal 2025-26, has been pushed to calendar 2028. Management acknowledged a multi-year delay on the conference call.
- How serious is the situation in Uganda?
- Receivable days have worsened to 320 from a previously disclosed 120-135 days. This means Unihealth is waiting almost a year for payment, which ties up capital and increases risk of bad debts.
- What is the status of the Tanzania strategy?
- The company has abandoned a previously promoted syringe manufacturing facility without explanation. It now plans a 20-bed secondary care facility in Mwanza awaiting regulatory approval and a 100-bed acquisition in Dar es Salaam at final legal stages.
An independent reading of the company's own disclosure — the primary filing above is the final word.